BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 31662221)

  • 1. Revisiting the non-Gaucher-GBA-E326K carrier state: Is it sufficient to increase Parkinson's disease risk?
    Goldstein O; Gana-Weisz M; Cohen-Avinoam D; Shiner T; Thaler A; Cedarbaum JM; John S; Lalioti M; Gurevich T; Bar-Shira A; Mirelman A; Giladi N; Orr-Urtreger A
    Mol Genet Metab; 2019 Dec; 128(4):470-475. PubMed ID: 31662221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
    Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
    Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age at Onset of Parkinson's Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations.
    Yahalom G; Rigbi A; Israeli-Korn S; Krohn L; Rudakou U; Ruskey JA; Benshimol L; Tsafnat T; Gan-Or Z; Hassin-Baer S; Greenbaum L
    J Parkinsons Dis; 2020; 10(3):1123-1132. PubMed ID: 32310186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset.
    Gan-Or Z; Giladi N; Rozovski U; Shifrin C; Rosner S; Gurevich T; Bar-Shira A; Orr-Urtreger A
    Neurology; 2008 Jun; 70(24):2277-83. PubMed ID: 18434642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease.
    Clark LN; Ross BM; Wang Y; Mejia-Santana H; Harris J; Louis ED; Cote LJ; Andrews H; Fahn S; Waters C; Ford B; Frucht S; Ottman R; Marder K
    Neurology; 2007 Sep; 69(12):1270-7. PubMed ID: 17875915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homozygosity for the MTX1 c.184T>A (p.S63T) alteration modifies the age of onset in GBA-associated Parkinson's disease.
    Gan-Or Z; Bar-Shira A; Gurevich T; Giladi N; Orr-Urtreger A
    Neurogenetics; 2011 Nov; 12(4):325-32. PubMed ID: 21837367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LRRK2, GBA and SMPD1 Founder Mutations and Parkinson's Disease in Ashkenazi Jews.
    Dagan E; Schlesinger I; Kurolap A; Ayoub M; Nassar M; Peretz-Aharon J; Gershoni-Baruch R
    Dement Geriatr Cogn Disord; 2016; 42(1-2):1-6. PubMed ID: 27449028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations.
    Yahalom G; Greenbaum L; Israeli-Korn S; Fay-Karmon T; Livneh V; Ruskey JA; Roncière L; Alam A; Gan-Or Z; Hassin-Baer S
    Parkinsonism Relat Disord; 2019 May; 62():179-184. PubMed ID: 30573413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in the glucocerebrosidase gene are common in patients with Parkinson's disease from Eastern Canada.
    Han F; Grimes DA; Li F; Wang T; Yu Z; Song N; Wu S; Racacho L; Bulman DE
    Int J Neurosci; 2016; 126(5):415-21. PubMed ID: 26000814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews.
    Aharon-Peretz J; Rosenbaum H; Gershoni-Baruch R
    N Engl J Med; 2004 Nov; 351(19):1972-7. PubMed ID: 15525722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The GBA variant E326K is associated with Parkinson's disease and explains a genome-wide association signal.
    Berge-Seidl V; Pihlstrøm L; Maple-Grødem J; Forsgren L; Linder J; Larsen JP; Tysnes OB; Toft M
    Neurosci Lett; 2017 Sep; 658():48-52. PubMed ID: 28830825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews.
    Dagan E; Schlesinger I; Ayoub M; Mory A; Nassar M; Kurolap A; Peretz-Aharon J; Gershoni-Baruch R
    Parkinsonism Relat Disord; 2015 Sep; 21(9):1067-71. PubMed ID: 26169695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variants in PSMB9 and FGR differentially affect Parkinson's disease risk in GBA and LRRK2 mutation carriers.
    Shani S; Goldstein O; Gana-Weisz M; Bar-Shira A; Thaler A; Gurevich T; Mirelman A; Giladi N; Alcalay RN; Orr-Urtreger A
    Parkinsonism Relat Disord; 2023 Jun; 111():105398. PubMed ID: 37116292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease.
    Ruskey JA; Greenbaum L; Roncière L; Alam A; Spiegelman D; Liong C; Levy OA; Waters C; Fahn S; Marder KS; Chung W; Yahalom G; Israeli-Korn S; Livneh V; Fay-Karmon T; Alcalay RN; Hassin-Baer S; Gan-Or Z
    Eur J Med Genet; 2019 Jan; 62(1):65-69. PubMed ID: 29842932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strong association between glucocerebrosidase mutations and Parkinson's disease in Sweden.
    Ran C; Brodin L; Forsgren L; Westerlund M; Ramezani M; Gellhaar S; Xiang F; Fardell C; Nissbrandt H; Söderkvist P; Puschmann A; Ygland E; Olson L; Willows T; Johansson A; Sydow O; Wirdefeldt K; Galter D; Svenningsson P; Belin AC
    Neurobiol Aging; 2016 Sep; 45():212.e5-212.e11. PubMed ID: 27255555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational modelling approaches as a potential platform to understand the molecular genetics association between Parkinson's and Gaucher diseases.
    Thirumal Kumar D; Eldous HG; Mahgoub ZA; George Priya Doss C; Zayed H
    Metab Brain Dis; 2018 Dec; 33(6):1835-1847. PubMed ID: 29978341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes.
    Alcalay RN; Dinur T; Quinn T; Sakanaka K; Levy O; Waters C; Fahn S; Dorovski T; Chung WK; Pauciulo M; Nichols W; Rana HQ; Balwani M; Bier L; Elstein D; Zimran A
    JAMA Neurol; 2014 Jun; 71(6):752-7. PubMed ID: 24756352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease.
    Davis MY; Johnson CO; Leverenz JB; Weintraub D; Trojanowski JQ; Chen-Plotkin A; Van Deerlin VM; Quinn JF; Chung KA; Peterson-Hiller AL; Rosenthal LS; Dawson TM; Albert MS; Goldman JG; Stebbins GT; Bernard B; Wszolek ZK; Ross OA; Dickson DW; Eidelberg D; Mattis PJ; Niethammer M; Yearout D; Hu SC; Cholerton BA; Smith M; Mata IF; Montine TJ; Edwards KL; Zabetian CP
    JAMA Neurol; 2016 Oct; 73(10):1217-1224. PubMed ID: 27571329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.
    Sidransky E; Nalls MA; Aasly JO; Aharon-Peretz J; Annesi G; Barbosa ER; Bar-Shira A; Berg D; Bras J; Brice A; Chen CM; Clark LN; Condroyer C; De Marco EV; Dürr A; Eblan MJ; Fahn S; Farrer MJ; Fung HC; Gan-Or Z; Gasser T; Gershoni-Baruch R; Giladi N; Griffith A; Gurevich T; Januario C; Kropp P; Lang AE; Lee-Chen GJ; Lesage S; Marder K; Mata IF; Mirelman A; Mitsui J; Mizuta I; Nicoletti G; Oliveira C; Ottman R; Orr-Urtreger A; Pereira LV; Quattrone A; Rogaeva E; Rolfs A; Rosenbaum H; Rozenberg R; Samii A; Samaddar T; Schulte C; Sharma M; Singleton A; Spitz M; Tan EK; Tayebi N; Toda T; Troiano AR; Tsuji S; Wittstock M; Wolfsberg TG; Wu YR; Zabetian CP; Zhao Y; Ziegler SG
    N Engl J Med; 2009 Oct; 361(17):1651-61. PubMed ID: 19846850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in glucocerebrosidase are a major genetic risk factor for Parkinson's disease and increase susceptibility to dementia in a Flanders-Belgian cohort.
    Crosiers D; Verstraeten A; Wauters E; Engelborghs S; Peeters K; Mattheijssens M; De Deyn PP; Theuns J; Van Broeckhoven C; Cras P
    Neurosci Lett; 2016 Aug; 629():160-164. PubMed ID: 27397011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.